CALT News and Press, Calliditas Therapeutics AB From 10/07/21

Calliditas announces acquisition of remaining Genkyotex minority shares PR Newswire STOCKHOLM , Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100...

A list of 62 recent IPOs debuted on The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 reconstitution. Following up on our previous article on recently-IPOd biotech stocks joining the index, in this article, we discuss another four biotechs ma...

Updated regulatory timeline for review of MAA in Europe PR Newswire STOCKHOLM , Sept. 16, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq: CALT), a biopharma company focused on identifying...

Gainers: Ampio Pharmaceuticals (NYSE:AMPE) +22%, 180 Life Sciences (NASDAQ:ATNF) +17%, Brainstorm Cell Therapeutics (NASDAQ:BCLI) +15%, Instil Bio (NASDAQ:TIL) +16%, G Medical Innovations (NASDAQ:GMVD) +15%. Losers: Nuwellis (NASDAQ:NUWE) -26%...

PDUFA goal date extension for Nefecon NDA in the U.S. PR Newswire STOCKHOLM , Sept. 14, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq – CALT) , a biopharma company focuse...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology  companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...

Shares of Travere Therapeutics remain well below this year's highs despite PROTECT study success. The regulatory update on the FSGS indication of sparsentan has weighed on the share price along with the poor biotech sentiment. While there is uncertainty for the FSGS indication, th...

Calliditas Therapeutics: Interim Report Q2, 2021 Filing of Marketing Authorisation Application on accelerated basis with EMA PR Newswire STOCKHOLM , Aug. 19, 2021 /PRNewswire/ -- "Following the filing for accelerated approval with the FDA in Q1, we filed our ...